KPV

TripeptideRx: ResearchCompound: Research

Also known as: alpha-MSH(11-13), KPV tripeptide, Lys-Pro-Val, Lysine-Proline-Valine

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source KPV at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) with potent anti-inflammatory properties. It lacks the melanotropic activity of full-length α-MSH while retaining immunomodulatory effects, making it a candidate for inflammatory and autoimmune conditions.

Mechanism of Action

alpha-MSH derivative with anti-inflammatory and immunomodulatory effects; acts via MC1R-independent pathways, inhibiting NF-κB activation and reducing pro-inflammatory cytokine production

Routes of Administration

IntravenousOralSubcutaneousTopical

Goals & Uses

  • Autoimmune disease modulationImmunologyLow
  • Wound healingDermatologicModerateTissue repair and wound healing
  • Anti-inflammatory therapyTherapeuticModerate
  • Cosmetic/dermatologicalTherapeuticLow

Contraindications

  • Active malignancyOncologyModerateUse caution or avoid depending on agent and context
  • hypersensitivity to peptide componentsAllergyModerate

Adverse Effects

  • Local injection site reactionLocalUnknown
  • Immunosuppression-related infectionImmunologicalUnknown

Drug Interactions

  • Immunosuppressants (biologics)Moderate
  • CorticosteroidsModerate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Pediatric populationsAgeRelative
  • Severe immunocompromiseImmunologicalRelative

Regulatory Status

  • European UnionUnapprovedNo MAA submitted; not listed in EMA databases
  • United StatesUnapprovedNo IND or NDA filed; research use only
  • United KingdomUnapprovedNo UK marketing authorization; MHRA database negative

Not approved for any indication; remains in preclinical and early research phases. No formal regulatory submissions identified.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is KPV?

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) with potent anti-inflammatory properties. It lacks the melanotropic activity of full-length α-MSH while retaining immunomodulatory effects, making it a candidate for inflammatory and autoimmune conditions.

What is KPV used for?

KPV is educationally associated with: Autoimmune disease modulation, Wound healing, Anti-inflammatory therapy, Cosmetic/dermatological. Educational only — not medical advice.

How is KPV administered?

Recorded routes of administration: Intravenous, Oral, Subcutaneous, Topical.

What are the potential side effects of KPV?

Reported adverse effects include: Local injection site reaction, Immunosuppression-related infection. This list is not exhaustive — consult a qualified clinician.

Who should avoid KPV?

Recorded contraindications: Active malignancy, hypersensitivity to peptide components. Consult a qualified clinician before use.